PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Cisplatin|DRUG: Rucaparib|DRUG: Cisplatin
Sponsor: Hoosier Cancer Research Network
Collaborators: Clovis Oncology, Inc.